Navigation Links
CryoCath to present at Piper Jaffray and BMO Healthcare conferences
Date:11/27/2007

Toronto Stock Exchange Symbol: CYT

MONTREAL, Nov. 27 /PRNewswire-FirstCall/ - CryoCath Technologies Inc. (TSX: CYT), the global leader in cryotherapy products to treat cardiac arrhythmias, today announced that Jan Keltjens, President and CEO of CryoCath, will present at both the Piper Jaffray 19th Annual Health Care Conference and the BMO Focus on Healthcare Conference. The Piper Jaffray Conference presentation will take place today at 1:50 pm ET at the Pierre Hotel in New York City and the BMO Conference will take place on Wednesday, December 5 at 2:00 pm ET at the Millenium Broadway Hotel in New York City. Both events will feature a market outlook and discuss some recent events and upcoming milestones, including the STOP AF IDE Trial for Arctic Front(R), the Company's minimally invasive cryo-balloon catheter designed specifically to treat paroxysmal atrial fibrillation.

The BMO Focus on Healthcare Conference will be accompanied by a live webcast of Mr. Keltjens' presentation, available at http://www.cryocath.com.

About CryoCath

CryoCath - http://www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiovascular disease. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.

This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factor
'/>"/>

SOURCE CryoCath Technologies Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. CryoCath files patent infringement lawsuit
2. CryoCath to present at CIBC Healthcare Conference
3. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
5. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
6. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
7. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
8. AtriCure to Present at Roth Capital Partners 2007 New York Conference
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. MDS to Present at Thomas Weisel Partners Healthcare Conference
11. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... military personnel who served in Iraq and Afghanistan ... injury (TBI) were compared to military personnel without ... Differences in measures of overall disability, cognitive function, ... are reported in an article in Journal ... Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... (April 16, 2014) The cause of neuronal death ... study proposes that neurons may be mistaken for foreign ... similar to the way autoimmune diseases like type I ... cells. The study was published April 16, 2014, in ... and likely controversial, idea in Parkinson,s disease; but if ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2
... revenue growth of 9.3 percent (constant currency) - ... updates annual financial guidance based on year-to-date ... performance and operational momentum, BATESVILLE, ... announced unaudited financial results for its fiscal,third quarter ended June ...
... A drug-like molecule called Wnt can be substituted ... added to adult cells to reprogram them to an ... such embryonic stem-cell-like cells, known as induced pluripotent (IPS) ... and diabetes. , Demonstrated in mice, the elimination ...
... Listed on OTCBB, DALIAN, China, Aug. 6 ... CHHB) (,China,Bio-Immunity" or "the Company,), today announced that ... Lawford Asia Limited (,Lawford,).,According to the share exchange ... and outstanding stock of Lawford in exchange for,the ...
... Inc.,(Nasdaq: XTNT ) today reported financial results for the ... an update on its business., The company reported a ... second quarter of 2008, compared to a net loss of ... 2007. The company,s net loss for,the second quarter of 2008 ...
... and year-to-date orders increase four percent from prior year,s ... periods, strong cash flow generation continues, ... (Nasdaq: CPII ), the parent company of Communications ... frequency, power,and control solutions for critical defense, communications, medical,scientific ...
... , , WEDNESDAY, Aug. 6 (HealthDay News) -- Stroke patients who ... likely to die in the hospital or be heavily disabled ... study suggests. , The finding is based on an ... an ischemic stroke. Ischemic strokes are the most common type ...
Cached Medicine News:Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 2Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 3Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 4Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 5Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 6Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 7Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 8Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 9Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 10Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 11Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 12Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 13Health News:Hill-Rom Reports Third Quarter Revenue Growth of 11.7 Percent to $366.8 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.34, an Increase of 89 Percent From the Prior Year 14Health News:Recipe for cell reprogramming adds protein 2Health News:China Bio-Immunity Corporation Completes Share Exchange and Reverse Merger 2Health News:China Bio-Immunity Corporation Completes Share Exchange and Reverse Merger 3Health News:China Bio-Immunity Corporation Completes Share Exchange and Reverse Merger 4Health News:XTENT Announces Second Quarter 2008 Financial Results and Business Progress 2Health News:XTENT Announces Second Quarter 2008 Financial Results and Business Progress 3Health News:XTENT Announces Second Quarter 2008 Financial Results and Business Progress 4Health News:XTENT Announces Second Quarter 2008 Financial Results and Business Progress 5Health News:CPI International Announces Third Quarter 2008 Financial Results 2Health News:CPI International Announces Third Quarter 2008 Financial Results 3Health News:CPI International Announces Third Quarter 2008 Financial Results 4Health News:CPI International Announces Third Quarter 2008 Financial Results 5Health News:CPI International Announces Third Quarter 2008 Financial Results 6Health News:CPI International Announces Third Quarter 2008 Financial Results 7Health News:CPI International Announces Third Quarter 2008 Financial Results 8Health News:CPI International Announces Third Quarter 2008 Financial Results 9Health News:CPI International Announces Third Quarter 2008 Financial Results 10Health News:CPI International Announces Third Quarter 2008 Financial Results 11Health News:CPI International Announces Third Quarter 2008 Financial Results 12Health News:CPI International Announces Third Quarter 2008 Financial Results 13Health News:CPI International Announces Third Quarter 2008 Financial Results 14Health News:CPI International Announces Third Quarter 2008 Financial Results 15
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines ...
... Portex® Thermovent® T helps provide protection to the ... small and extremely lightweight making it ideal for ... a high rate of heat and moisture recovery, ... ,All HMEs and filters have ISO standard ...
circuitGuard™ Products are available in filter or filter/HME styles., ,High quality air cushion anesthesia masks may be packaged with any circuitGuard™ product....
... Since 1991 Intersurgical ... breathing filters, heat and ... oxygen therapy products, hand-held ... range of accessories and ...
Medicine Products: